MENU
Aim higher

PROMISE

Development of a novel microbiota-based therapy for the prevention of type 2 diabetes mellitus.

PROMISE will deliver an innovative microbiota-based therapy based upon the anaerobic human derived butyrate-producing bacterium Eubacterium hallii, for the reduction of insulin resistance and prevention of type 2 diabetes mellitus (T2DM) in individuals suffering from metabolic syndrome (MetS). Additionally, this project adopts a novel approach aiming to set new standards in performing (pre)clinical studies using a microbial therapy in stratified target groups.
Acronym: 
PROMISE
Project ID: 
12 091
Ranking: 
70
Cut-off: 
8
Start date: 
01-05-2018
Project Duration: 
36months
Project costs: 
1 872 200.00€
Technological Area: 
Nutrition and Health
Market Area: 
Therapeutic